DDP-38003 dihydrochloride is primarily investigated for its potential therapeutic applications, particularly in the field of oncology. It is studied for its role as a targeted inhibitor, showing promise in disrupting specific pathways involved in cancer cell proliferation and survival. Researchers are exploring its efficacy in treating various types of cancers, including those resistant to conventional therapies. Additionally, it is being evaluated for its ability to enhance the effectiveness of existing treatments when used in combination therapies. Its mechanism of action focuses on modulating key molecular targets, making it a candidate for precision medicine approaches. Ongoing preclinical and clinical studies aim to determine its safety, pharmacokinetics, and potential as a novel anticancer agent.